Metastatic Colorectal Cancer Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Caribou Biosciences, Intimia Biosciences, Excision Biotherapeutics

DelveInsight Business Research LLP

DelveInsight’s “Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Metastatic Colorectal Cancer  

• In the past, 15 years ago, the median overall survival (MOS) was approximately 12 months, and the 5-year survival rate was 13%. However, the survival rate of these patients has increased, mainly due to the combined treatment of metastases with surgery and systemic therapy. Long-term survival or even cure can be attained in 20–50% of the patients who undergo complete R0 resection of liver or lung metastases, and around 70% 5-year survival of these patients can be achieved.

Metastatic Colorectal Cancer Overview

Metastatic CRC may consist of tumors identified at a distant site following a previously treated localized CRC (nonmetastatic or stage I-III) or may present de novo at stage IV, defined as metastatic disease or cancer that has spread outside the original colorectal mass.

Discover more about the emerging Metastatic Colorectal Cancer  drugs@ Metastatic Colorectal Cancer Treatment Drugs

Metastatic Colorectal Cancer Key Companies 

• Alexion Pharmaceuticals

• GlaxoSmithKline (GSK)

• Pfizer

• Eli Lilly

• Taiho Oncology

• Bristol-Myers Squibb

• Amgen

And many others 

Metastatic Colorectal Cancer Therapies 

• Bevacizumab

•  Regorafenib

•  Capecitabine

•  Cyclophosphamide

•  Capecitabine

•  BPI-421286

And many others 

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services